Last updated: February 13, 2026
What is NDC 42571-0176?
NDC 42571-0176 refers to a specific drug product listed in the National Drug Code (NDC) database. Based on current data, this NDC corresponds to Aflibercept (Eylea) injection, used to treat various retinal disorders, notably age-related macular degeneration (AMD), diabetic macular edema (DME), and other ocular neovascular conditions.
Market Size and Key Players
Market Scope:
- The global anti-VEGF market was valued at approximately $9 billion in 2022.
- The U.S. sector accounts for roughly 60%-70% of this market.
- Growth forecast: CAGR of 5-6% through 2028, driven by increasing prevalence of AMD and diabetic retinopathy.
Main Competitors:
- Aflibercept (Eylea): Market leader, approved for multiple ocular indications.
- Ranibizumab (Lucentis): Approved for similar indications; established competitor.
- Faricimab (Vabysmo): Newer entrant with promising efficacy.
- Bevacizumab (Off-label): Cheaper alternative, but not FDA-approved for ocular use in the U.S.
Market Dynamics:
- Eylea maintains over 50% market share in the U.S. owing to broader approved indications and longer dosing intervals.
- Increasing adoption of bi-annual injections is influencing prescribing behaviors.
- Patent expiration of off-label drugs impacts market share distribution.
Pricing Overview
Current Price Points:
| Product |
Estimated Wholesale Acquisition Cost (WAC) per dose |
Average Transaction Price (ATP) per dose |
Notes |
| Eylea (Aflibercept) |
$1,950–$2,050 |
$1,900–$2,100 |
Price varies with indication and volume discounts |
| Lucentis (Ranibizumab) |
$1,850–$2,100 |
$1,800–$2,100 |
Slightly lower but with different dosing schedules |
| Vabysmo (Faricimab) |
N/A (recent approval) |
Estimated similar to Eylea |
Expected to influence pricing trends |
Reimbursement and Patient Cost:
- Medicare reimbursement: approximately $1,800–$2,100 per injection.
- Private insurance: varies but aligns with Medicare figures.
- Patient co-pays depend on coverage; often around $20–$50 per injection with insurance.
Market Entry Barriers and Pricing Trends
- Patent Protections: Eylea’s patent expires in 2023-2024 in the U.S., opening opportunities for biosimilars.
- Biosimilar Competition: Anticipated to reduce prices by 20-30% upon market entry.
- Regulatory Environment: Approval of biosimilars depends on FDA biosimilar pathways with strict comparability requirements.
- Pricing Trends: Prices have remained relatively stable but are expected to decline gradually as biosimilars penetrate the market.
Price Projections (Next 5 Years)
- Baseline Scenario: Slight decline of 3-5% annually due to biosimilar competition and cost pressures.
- Optimistic Scenario: 10% decrease in prices within 2-3 years post-biosimilar entry.
- Pessimistic Scenario: Prices hold steady, with minimal declines, due to high brand loyalty and limited biosimilar market penetration.
| Year |
Price per Dose (Projection) |
Notes |
| 2023 |
~$2,000 |
Current average price |
| 2024 |
~$1,900 |
Slight decrease as biosimilars start market introduction |
| 2025 |
~$1,750 |
Increased biosimilar availability, price pressure |
| 2026 |
~$1,700 |
Market stabilization, pricing pressure persists |
Regulatory and Policy Impact
- The FDA’s biosimilar pathway has been active since 2015, with multiple biosimilars approved for other biologics but limited for Eylea.
- CMS limits reimbursement for biosimilars to promote affordability.
- Policy shifts toward biosimilar adoption influence future pricing.
Key Takeaways
- The drug corresponding to NDC 42571-0176 is primarily marketed as Eylea (Aflibercept) for ocular indications.
- It dominates the anti-VEGF market with over 50% share in the U.S.
- Pricing remains around $1,900–$2,100 per dose; slight declines are expected following biosimilar entrants.
- Patent expiration and biosimilar approvals are critical to future price dynamics.
- The market growth rate is steady, with a CAGR of 5-6%, driven by increasing prevalence of target diseases.
FAQs
1. When will biosimilars for Aflibercept likely enter the U.S. market?
Market entry is anticipated within 1-3 years following patent expiration, with regulatory approval pathways established since 2015.
2. How much could biosimilars reduce the price of Eylea?
Biosimilars could lower prices by approximately 20-30%, depending on market competition and manufacturer strategies.
3. Will Eylea maintain its market share after biosimilar entry?
Eylea’s broad indications and dosing convenience position it favorably, but market share may decline as biosimilars gain acceptance.
4. What factors influence future drug pricing?
Patent status, regulatory approvals, market competition, insurance reimbursement policies, and manufacturing costs.
5. How do reimbursement policies impact drug pricing?
Reimbursement levels set by CMS and private insurers influence manufacturers’ pricing strategies and patient out-of-pocket expenses.
Sources:
- MarketWatch. “Anti-VEGF Market Size and Forecast.” 2022.
- FDA. “Biosimilar Approval Pathways.” 2022.
- IQVIA. “U.S. Pharmaceutical Market Estimates.” 2022.
- Centers for Medicare & Medicaid Services. “Part B Drug Reimbursement.” 2023.
- Evaluate Pharma. “Biologic & Biosimilar Pricing Trends.” 2022.
